1072102-01-2

Upstream product

• 1072102-00-1 C₁₄H₂₀N₂O₃*ClH 
• 159999-80-1 N-benzyl-N-Boc-L-alanine 
• 1072101-99-5 C₁₉H₂₈N₂O₅ 
• 1254043-76-9 (S)-methyl 2-{(R)-N-benzyl-2-[(tert-butoxycarbonyl)amino]propane amide}propanoate 

Downstream Products

• 431062-00-9 4-benzyl-2R,5S-dimethyl-piperazine-1-carboxylic acid tert-butyl ester 
• 216532-43-3 (-)-(2R,5S)-1-benzyl-2,5-dimethylpiperazine 
• 260254-80-6 trans-2R,5S-dimethyl-4-benzyl-piperazine 
• 1046788-31-1 4-(((2R,5S)-4-benzyl-2,5-dimethylpiperazin-1-yl)methyl)tetrahydro-2H-pyran-4-ol 

Relevant academic research and scientific papers

Asymmetric synthesis of 3,4,6-trisubstituted 2,5-diketopiperazines by using dynamic kinetic resolution of α-bromo tertiary acetamides

A new and efficient method for the asymmetric synthesis of 3,4,6-trisubstituted 2,5-diketopiperazines has been developed. The dynamic kinetic resolution of L-amino-acid-derived α-bromo tertiary amides in the nucleophilic substitution reaction with p-anisi

CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER

[Object] It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C—R7; each X and Y independently show CH2, C═O, SO2, etc; Z shows CH or N; each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.; R3 shows C1-8 alkyl group; R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group; R5 and R6 show a hydrogen atom, etc.; L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)

3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C

The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ